Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 3Phase 1/2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 8Thoracic 4Gastrointestinal 4Head & Neck 3Gynecologic 3Genitourinary 3Dermatologic 2Breast 2Tumor-Agnostic 1Plasma cell 1Lymphoid 1

Conditions

Carcinoma, Renal Cell 3Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Ovarian Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Melanoma 1Kidney Neoplasms 1Esophageal Neoplasms 1Erythrocytosis, Familial, 4 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Merkel Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 93Nivolumab 61Docetaxel 55Cyclophosphamide 49enzalutamide 44Magnetic Resonance Spectroscopy 33Ipilimumab 33Gemcitabine 32Abiraterone Acetate 30Prednisone 29fludarabine 28Everolimus 27Paclitaxel 25Cisplatin 24Radiotherapy 23Carboplatin 23Sunitinib 22cabozantinib 21atezolizumab 20Radiosurgery 20Specimen Handling 19Sorafenib 18Bevacizumab 18pazopanib 17bicalutamide 17abiraterone 17Biopsy 15temsirolimus 14darolutamide 14apalutamide 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × zimberelimab × Genitourinary × Clear all
NCT05536141 2026-05-01

ARC-20

Arcus Biosciences, Inc.

Phase 1 Recruiting
362 enrolled
Genitourinary

Erythrocytosis, Familial, 4, Carcinoma, Renal Cell, Kidney Neoplasms

NCT05891171 2026-03-31

ARC-25

Arcus Biosciences, Inc.

Phase 1 Active not recruiting
40 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT03629756 2024-05-24

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Arcus Biosciences, Inc.

Phase 1 Completed
48 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡